Galderma Announces Topline Results of OLYMPIA 2 Study Evaluating Nemolizumab in Prurigo Nodularis

TOKYO, June 22, 2022 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that Galderma issued a press release on June 22 regarding positive topline results of a phase III clinical study, in prurigo nodularis (OLYMPIA 2) for the humanized anti-human IL-31 receptor A monoclonal antibody nemolizumab, created by Chugai. Clinical development of nemolizumab outside Japan has been conducted by Galderma. Please refer to the link below for details of the press release: Galderma announces positive data from phase III trial, demonstrating efficacy and safety of nemolizumab in patients with prurigo nodularis https://www.galderma.com/news/galderma-announces-positive-data-phase-iii-trial-demonstrating-efficacy-and-safety-nemolizumab

The release as fetched from its publisher. chugai-pharm.co.jp ↗